The aim of this paper is to estimate the relative cost-effectiveness of treatment regimens for managing patients with sciatica. A deterministic model structure was constructed based on information from the findings from a systematic review of clinical effectiveness and cost-effectiveness, published sources of unit costs, and expert opinion. The assumption was that patients presenting with sciatica would be managed through one of 3 pathways (primary care, stepped approach, immediate referral to surgery). Results were expressed as incremental cost per patient with symptoms successfully resolved. Analysis also included incremental cost per utility gained over a 12-month period. One-way sensitivity analyses were used to address uncertainty. The model demonstrated that none of the strategies resulted in 100% success. For initial treatments, the most successful regime in the first pathway was nonopioids, with a probability of success of 0.613. In the second pathway, the most successful strategy was nonopioids, followed by biological agents, followed by epidural/nerve block and disk surgery, with a probability of success of 0.996. Pathway 3 (immediate surgery) was not cost-effective. Sensitivity analyses identified that the use of the highest cost estimates results in a similar overall picture. While the estimates of cost per quality-adjusted life year are higher, the economic model demonstrated that stepped approaches based on initial treatment with nonopioids are likely to represent the most cost-effective regimens for the treatment of sciatica. However, development of alternative economic modelling approaches is required. Ó
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Introduction
Understanding the clinical effectiveness and cost-effectiveness of different management strategies for sciatica is important in order to prevent patients with acute or sub-acute symptoms developing a more chronic condition that is resistant to treatment and likely to incur high health care, socioeconomic costs, and impact on patient outcomes. It is well accepted that taking into account value for money is important in health care decisionmaking. This requires formal assessments of best available evidence on cost-effectiveness, and where necessary, undertaking economic modelling studies if there is a lack of good quality evidence.
Within the United Kingdom (UK), the prevalence of sciatica has been reported as 3.1% in men and 1.3% in women [11] , accounting for <5% of lower back pain cases presenting in primary care [23] . A large population study based in Finland found a lifetime prevalence of 5.3% in men and 3.7% in women [9] . Some cohort studies have reported that most patients will have a resolution of their sciatica over a period of weeks to months, with 30% having persistent, troublesome symptoms at 1 year, with 20% out of work and 5%-15% requiring surgery [2, 24] . However, another cohort study found that 55% still had symptoms of sciatica 2 years later, and 53% after 4 years (which included 25% who had recovered after 2 years but had relapsed by 4 years) [20] . As the sciatica becomes 
